


BGB-3111-304: P3 Open-label randomized study of BGB-3111 vs. B+R in previously untreated patients with CLL or SLL



a. Randomization will be stratified by age (< 65 years vs \geq 65 years), Binet stage (C vs A or B), geographic region (North America vs Europe vs Asia-Pacific) and IGHV mutational status (mutated vs unmutated).

b. Crossover from arm B to arm A is allowed after disease progression is confirmed by independent central review

Key Inclusion Criteria

- Previously untreated CD-20-positive CLL or SLL, unsuitable for treatment with FCR per investigator (eg, \geq 65 years of age, comorbidities [eg, CIRS score > 6], creatinine clearance < 70 mL/min, previous infections); Binet Stage C disease, or Binet Stage B or A disease requiring treatment

Key Exclusion Criteria

- Previous systemic treatment for CLL/SLL; Richter transformation or history of prolymphocytic leukemia; clinically significant cardiovascular disease; history of severe bleeding disorder